X4 Pharmaceuticals Receives European Commission Approval for XOLREMDI (Mavorixafor) as First WHIM Syndrome Treatment in EU

Key Takeaways

• European Commission grants marketing authorization for XOLREMDI (mavorixafor) as the first and only treatment for WHIM syndrome in the European Union
• Approval provides X4 Pharmaceuticals with market exclusivity for treating this ultra-rare hematology condition affecting immune function
• Decision follows positive recommendation from European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP)

---

BOSTON - X4 Pharmaceuticals (Nasdaq: XFOR) announced April 29, 2026, that the European Commission has granted marketing authorization for XOLREMDI® (mavorixafor) capsules to treat patients with WHIM syndrome across the European Union, marking a significant regulatory milestone for the rare disease-focused biotechnology company.

The approval establishes XOLREMDI as the first and only authorized treatment for WHIM syndrome in the EU, providing X4 Pharmaceuticals with market exclusivity for this ultra-rare hematological condition. The decision follows a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP), validating the drug’s safety and efficacy profile.

Understanding WHIM Syndrome and Treatment Need

WHIM syndrome is an extremely rare primary immunodeficiency disorder characterized by warts, hypogammaglobulinemia, infections, and myelokathexis. Patients with this genetic condition experience severe immune system dysfunction, leading to recurrent infections and increased cancer risk due to neutrophil retention in bone marrow.

Mavorixafor functions as a CXCR4 antagonist, targeting the underlying mechanism that causes neutrophils to be trapped in bone marrow rather than circulating in the bloodstream where they can fight infections effectively.

Market Impact and Commercial Implications

The European approval represents a crucial expansion of X4 Pharmaceuticals’ commercial footprint beyond previous regulatory successes. As an orphan drug designation, XOLREMDI qualifies for extended market exclusivity periods and potential pricing premiums typical of rare disease treatments.

While the commercial opportunity remains limited due to WHIM syndrome’s ultra-rare nature, affecting fewer than 1,000 patients globally, the approval validates X4’s CXCR4 antagonist platform technology. This regulatory success could facilitate future development programs targeting other CXCR4-related conditions with larger patient populations.

Regulatory Pathway and Clinical Evidence

The European Commission’s decision was supported by comprehensive clinical trial data demonstrating mavorixafor’s ability to increase circulating neutrophil counts and reduce infection rates in WHIM syndrome patients. The approval follows established regulatory pathways for rare disease treatments, including orphan drug designation benefits.

Healthcare providers across the EU will now have access to prescribe XOLREMDI for eligible patients, addressing a significant unmet medical need in the rare hematology space. The company expects to begin commercial distribution through specialized rare disease pharmacy networks.

Future Outlook and Development Pipeline

This European approval strengthens X4 Pharmaceuticals’ position in the rare hematology market and provides important regulatory precedent for potential future indications. The company continues evaluating mavorixafor’s therapeutic potential in other CXCR4-mediated conditions, potentially expanding the addressable patient population.

The successful European regulatory process also demonstrates the robustness of X4’s clinical development capabilities and regulatory strategy, factors that could prove valuable for advancing other pipeline candidates targeting rare diseases with high unmet medical need.

---

Frequently Asked Questions

What does this approval mean for WHIM syndrome patients in Europe?

European WHIM syndrome patients now have access to the first authorized treatment specifically designed for their condition. XOLREMDI can help increase circulating neutrophil counts and reduce infection rates, addressing the underlying immune dysfunction characteristic of WHIM syndrome.

When will XOLREMDI be available to patients in the EU?

Following European Commission approval, X4 Pharmaceuticals will begin commercial distribution through specialized rare disease pharmacy networks. Exact availability timing may vary by individual EU member states based on local reimbursement and distribution processes.

How does XOLREMDI compare to existing WHIM syndrome treatments?

XOLREMDI is the first and only treatment specifically authorized for WHIM syndrome in the EU. Previously, patients relied on supportive care measures like antibiotics and immunoglobulin replacement therapy to manage symptoms rather than addressing the underlying cause of their immune dysfunction.